08
08HH.STU Shanghai Fosun Pharmaceutical (Group) Co. Ltd
- Market cap
- EUR 4.97B
- P/E
- 11.0x
- P/B
- 0.72x
- ROE
- 7.1%
- Dividend yield
- 2.72%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 08HH.STU undervalued?
Graham number08HH.STU trades 40.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Fosun Pharmaceutical (Group) Co. Ltd fundamental analysis
No fundamental analysis for Shanghai Fosun Pharmaceutical (Group) Co. Ltd yet.
Shanghai Fosun Pharmaceutical (Group) Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Fosun Pharmaceutical (Group) Co. Ltd
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company's product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural …
Full company profileShanghai Fosun Pharmaceutical (Group) Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Fosun Pharmaceutical (Group) Co. Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 14.6B | 18.5B | 24.9B | 28.6B | 30.3B | 39.0B | 44.0B | 41.4B | 41.1B | 41.7B | 40.6B |
| Gross Profit | 7.91B | 10.9B | 14.6B | 17.0B | 16.9B | 18.8B | 20.8B | 19.8B | 19.7B | 20.9B | 20.2B |
| Operating Income | 1.74B | 2.30B | 2.37B | 2.62B | 2.83B | 2.72B | 3.64B | 1.56B | 3.20B | 3.15B | 3.11B |
| EBITDA | - | 5.58B | 5.83B | 7.07B | 7.23B | 8.71B | 7.87B | 7.55B | 8.60B | 9.89B | 6.40B |
| Net Income | 2.81B | 3.12B | 2.71B | 3.32B | 3.66B | 4.74B | 3.73B | 2.39B | 2.77B | 3.37B | 3.56B |
| EPS | - | 1.25 | 1.06 | 1.30 | 1.43 | 1.85 | 1.40 | 0.89 | 1.04 | 1.26 | 1.33 |
| Balance Sheet | |||||||||||
| Total Assets | 43.8B | 62.0B | 70.6B | 76.1B | 83.7B | 93.3B | 107B | 113B | 117B | 120B | 127B |
| Total Liabilities | 18.5B | 32.2B | 37.0B | 36.9B | 37.7B | 44.9B | 53.1B | 56.9B | 57.5B | 58.2B | 60.7B |
| Shareholders' Equity | 22.2B | 25.3B | 28.0B | 31.9B | 37.0B | 39.2B | 44.6B | 45.7B | 47.3B | 48.7B | 50.3B |
| Cash & Short-term Investments | 6.00B | 7.25B | 8.55B | 9.53B | 9.96B | 10.3B | 16.2B | 13.7B | 13.5B | 13.1B | 13.3B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.11B | 2.58B | 2.95B | 3.22B | 2.58B | 3.94B | 4.22B | 3.41B | 4.48B | 5.21B | - |
| Capital Expenditure | 1.92B | 2.17B | 3.17B | 3.96B | 4.44B | 4.97B | 5.89B | 5.34B | 4.41B | 4.45B | 5.69B |
| Free Cash Flow | - | 410M | -225M | -740M | -1.86B | -1.02B | -1.67B | -1.92B | 66.8M | 765M | -1.12B |
| Ratios | |||||||||||
| ROE | 12.6% | 12.3% | 9.7% | 10.4% | 9.9% | 12.1% | 8.4% | 5.2% | 5.9% | 6.9% | 7.1% |
| ROA | 6.4% | 5.0% | 3.8% | 4.4% | 4.4% | 5.1% | 3.5% | 2.1% | 2.4% | 2.8% | 2.8% |
| Net Profit Margin | 19.2% | 16.9% | 10.9% | 11.6% | 12.1% | 12.1% | 8.5% | 5.8% | 6.7% | 8.1% | 8.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shanghai Fosun Pharmaceutical (Group) Co. Ltd dividends
- Dividend yield
- 2.72%
- Forward dividend
- 0.05 EUR
- Payout ratio
- 57.7%
- Ex-dividend date
- Jul 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.94B | 0.73 | 57.7% |
| 2024 | CNY 2.06B | 0.77 | 74.4% |
| 2023 | CNY 2.46B | 0.92 | 102.9% |
| 2022 | CNY 2.37B | 0.89 | 63.6% |
| 2021 | CNY 1.91B | 0.75 | 40.4% |
| 2020 | CNY 1.83B | 0.72 | 50.1% |
| 2019 | EUR 1.86B | 0.73 | 56.1% |
| 2018 | EUR 1.78B | 0.69 | 65.6% |
| 2017 | EUR 1.43B | 0.57 | 45.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai Fosun Pharmaceutical (Group) Co. Ltd
- Insiders 14.76%
- Institutions 25.83%
- Public & others 59.42%
- Shares outstanding 552M
- Free float 1.65B
Shanghai Fosun Pharmaceutical (Group) Co. Ltd company profile
- Company name
- Shanghai Fosun Pharmaceutical (Group) Co. Ltd
- Ticker
- 08HH.STU
- ISIN
- CNE100001M79
- Exchange
- Stuttgart Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 40,370
- Fiscal year end
- December
- Address
- Building A, Shanghai, China, 200233
- Phone
- 86 21 3398 7000
- Website
- fosunpharma.com
About Shanghai Fosun Pharmaceutical (Group) Co. Ltd
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company's product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III. It engages in the import and export of medical equipment; provision of related and other consulting services; medical devices and diagnosis products, and healthcare service; and investment management, as well as involves in the retail and wholesale distribution of medicines. The company was founded in 1994 and is based in Shanghai, China.
Shanghai Fosun Pharmaceutical (Group) Co. Ltd management
6- Ms. Xiaohui GuanExecutive Co-Chairman · born 1971
- Mr. Yuqing ChenExecutive Chairman · born 1975
- Dr. Yi LiuCEO, Chair of Fosun MedTech, Co-Chair of Innovative Medicines Division & Exec Director · born 1975
- Mr. Deyong WenExecutive Vice Chairman · born 1971
- Ms. Rongli FengExecutive President & Chief Human Resources Officer · born 1975
- Ms. Jing LiCo-President and CEO of Mature Products and Manufacturing Business Unit · born 1972